Antihypertensive effects of metolazone (zaroxolyn).
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001639:Bicarbonates / Q000097:blood; D001786:Blood Glucose; D001794:Blood Pressure; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000097:blood; D002712:Chlorides / Q000097:blood; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000378:metabolism; D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D010919:Placebos; D011799:Quinazolines / Q000627:therapeutic use*; D013449:Sulfonamides; D014527:Uric Acid / Q000097:blood
D000959:Antihypertensive Agents; D001639:Bicarbonates; D001786:Blood Glucose; D002712:Chlorides; D004232:Diuretics; D010919:Placebos; D011799:Quinazolines; D013449:Sulfonamides; D014527:Uric Acid; D003404:Creatinine; D002118:Calcium